CBN’s uncertainty is about what is doing the work. It is a weak partial agonist at CB1 in its own right, reaching roughly 29 percent of maximum effect where THC reaches 72 percent. But when rats were dosed with it, its metabolite 11-hydroxy-CBN reached brain concentrations equivalent to CBN itself, and that metabolite is a CB1 agonist with potency comparable to THC. So CBN’s central effects may be substantially the work of something CBN turns into, which is a different claim from CBN acting at a receptor.
CBC’s uncertainty is more basic: whether it reaches CB1 at all. One 2020 panel reported a Ki of 11 nanomolar at human CB1 and 68 percent of reference effect in a cAMP assay. But the 95 percent confidence interval around that figure ran from 1.9 to 91 nanomolar, and the authors attributed the spread to incomplete competition with the radioligand, calling the system noisy. A 2025 study using purified enantiomers found that only the minus form activated CB2, with an EC50 of 1.5 micromolar, and that CB1 activation appeared only at 30 micromolar, a concentration with no physiological meaning.
Those two results cannot both be right, and no human study exists to arbitrate.
For CBN the answer involves looking past the parent molecule. CBN is a rat TRPA1 agonist and desensitizer, and it inhibits threshold sodium currents in dorsal root ganglion neurons in a functionally selective way. But the potent cannabinoid-receptor activity belongs to 11-hydroxy-CBN, and that is also the most plausible explanation for CBN being weakly intoxicating at very high oral doses when its own CB1 efficacy is so low.
For CBC the strongest and least contested figure is at CB2: a cAMP EC50 of 7.1 nanomolar reaching 76 percent of reference effect in cells expressing the human receptor. The enantiomer work narrows that, because if only the minus form is active at CB2 then the potency of any given CBC material depends on its enantiomeric composition, and which form the plant’s synthase predominantly makes is not established. CBC also inhibits anandamide cellular uptake more strongly than CBD does.
Separately, CBC was incubated with human liver microsomes and its major metabolite identified as 2′-hydroxycannabicitran. Modeling predicted it would sit in the binding pocket of both cannabinoid receptors, and a binding assay then showed it binds neither.
Together the columns describe a category problem rather than two product stories. CBN has the only human data of the pair, a missed primary endpoint with positive secondary measures at a dose 60 to 100 times what products contain. CBC has no human data and a receptor profile two competent laboratories describe differently.
If evidence decides it, CBN is ahead only in the sense that something has been measured in people, and what was measured was a failure on the endpoint the trial was designed around. If mechanism decides it, CBC has the cleaner and more potent CB2 result, with its CB1 position unresolved.
The more useful approach treats both as questions about the product. In a full spectrum extract, CBC is naturally occurring plant material and a low CBN figure signals an extract that was handled and stored well. In an isolate, a large CBN number usually means THC was converted on purpose.
Still weighing up the options? See CBN vs CBD, CBC vs CBD or CBC vs CBG. Endoca products related to this comparison: CBN products.
Hemp-derived CBN and CBC have been treated as lawful while the source material stayed under the 2018 Farm Bill threshold of 0.3 percent delta-9 THC by dry weight.
From 11 December 2026 the test becomes total THC, finished products are capped at 0.4 milligrams of combined total THC per container, and Section 781 of Public Law 119-37 excludes cannabinoids synthesized outside the plant even where the molecule occurs in nature. CBN carries clear exposure, because concentrated CBN is normally produced by converting THC rather than extracting degraded material. CBC is ordinarily extracted, so the question there is the total THC content of the extract behind it. FDA has not published the lists the rule requires.
For CBN the available safety information comes from one trial of single doses in 20 adults, which recorded 247 mild to moderate adverse events across its arms and no serious ones. Single-night data in 20 people does not describe what nightly use does, and the dose that moved the secondary measures was 300 mg.
For CBC there is no human safety data at all, which is the only accurate thing to say about it. Its major human liver metabolite has been characterized in vitro, which tells us how the body would process it and nothing about tolerability. Neither compound has published human pharmacokinetics, and neither is authorized by FDA for use in a dietary supplement.
CBN and CBC are both on the HPLC panel for every batch, and we report them whatever the numbers say. For CBN that usually means publishing a low figure, which is the point: a low CBN result in a CBD extract is evidence the material was harvested, extracted and stored without the oxidation that produces it. The certificate cannot tell you which CBC enantiomer dominates, because that is not a routine measurement.
The one trial in people with diagnosed insomnia says not on its primary measure. Wake after sleep onset was not significantly reduced at either 30 or 300 mg. Several secondary measures did improve at 300 mg, but that dose is far above what products contain.
Nobody knows, because no controlled study has given CBC to a person. In cells it is potent at CB2, which is not associated with intoxication, and its CB1 activity is disputed between laboratories. An absence of reports is not evidence that it cannot cause any.
One reported a Ki of 11 nanomolar but with a confidence interval from 1.9 to 91 nanomolar, which the authors attributed to incomplete competition with the radioligand. Another, using purified enantiomers, found CB1 activation only at 30 micromolar. No human data exists to settle it.
They occur together in full spectrum extracts and no interaction between them has been documented. No study has tested the combination, so there is nothing to describe beyond the absence of a reported problem. The evidence for each alone remains thin.
Yes. CBN forms when THC oxidises as cannabis ages or is exposed to heat and light. CBC is different: the plant makes it directly from CBGA.
Often in small amounts. The batch certificate of analysis shows whether, and how much, of each is present.
Arnold JC et al. A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats. Neuropsychopharmacology 2025;50:586-595.
Lavender IG et al. Cannabinol for acute treatment of insomnia disorder in a randomized placebo-controlled crossover trial. J Sleep Res 2026;35:e70284.
Showalter VM et al. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands. J Pharmacol Exp Ther 1996;278:989-999.
Udoh M et al. Activation of CB2 receptors by (-)-cannabichromene but not (+)-cannabichromene. Cannabis Cannabinoid Res 2025;10:e94-e101.
Zagzoog A et al. In vitro and in vivo pharmacological activity of minor cannabinoids isolated from Cannabis sativa. Sci Rep 2020;10:20405.
De Petrocellis L et al. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 2011;163:1479-1494.
Ward AM et al. Identification and characterization of cannabichromene’s major metabolite following incubation with human liver microsomes. Metabolites 2024;14:329.
Ghovanloo MR et al. Functionally-selective inhibition of threshold sodium currents and excitability in dorsal root ganglion neurons by cannabinol. Commun Biol 2024;7:120.
Congressional Research Service. Changes to the statutory definition of hemp and issues for Congress. In Focus IF13136, 17 August 2026.
Last reviewed 6 October 2026.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.